Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 197

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 197
---
 of pre-funded warrants. As
of September 30, 2025, 10,787 pre-funded warrants remain exercisable.

The Warrants have an exercise
price of $39.20 per share, are immediately exercisable upon stockholder approval and have a term of exercise equal to five years following
the initial exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment
in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price.

In connection with the Offering,
on February 5, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Alliance
Global Partners (“A.G.P.”), as the exclusive placement agent in connection with the Offering (the “Placement Agent”).
Pursuant to a side letter between the Placement Agent and JonesTrading Institutional Services LLC (“Jones”), dated February
3, 2025, Jones agreed to be a financial advisor for the Offering. In connection with the services provided by Jones, the Placement Agent
and Jones agreed that the Placement Agent will receive an aggregate fee equal to 6% of the gross proceeds received in the Offering and
Jones will receive an aggregate fee equal to 3% of the gross proceeds received in the Offering. In addition, the Company agreed to reimburse
the Placement Agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $85,000, non-accountable expenses
of up to $25,000 and has agreed to reimburse Jones for all reasonable and documented out-of-pocket fees and expenses, including but not
limited to travel and other out-of-pocket expenses in an amount not to exceed $15,000.

The Company’s directors
and executive officers agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose
of any shares of common stock or other securities convertible into or exercisable or exchangeable for common stock for a period of 90
days following the closing date of the Offering, which terms may be waived in the sole discretion of and without notice by the Placement
Agent, subject to certain exceptions. In addition, the Company has agreed to not enter into variable rate financings for a period of 180
days following the closing date, subject to certain exceptions, or enter into any equity financings for a period of 60 days following
the closing date, subject to certain exceptions.

22